BV6 is a small molecule, bivalent IAP antagonist that binds to the c-IAP1 and XIAP BIR2-BIR3 domains with Kd of 0.46 and 0.029 nM, respectively.
BV6 treatment results in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs.
BV6 also induces induce TNFα-dependent cell death, exhibits single-agent cell killing activity in EVSA-T cell line (IC50=14 nM).
